CureVac NV Ordinary Shares
CVAC: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $25.60 | Kwyl | Qmglcdrmx |
CureVac Provides Very Risk-Tolerant Investors With Exposure to Early-Stage mRNA Pipeline Candidates
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
Business Strategy and Outlook
CureVac was founded in 2000, and its focus is on developing vaccines and therapies using messenger ribonucleic acid, or mRNA. mRNA offers several advantages, including cell-free, rapid, large-scale manufacturing and the ability to substitute new genetic sequences to create novel vaccines. Vaccines are typically composed of weakened viruses or proteins (antigens) that they express. In mRNA vaccines, the genetic code for an antigen is administered to patients who then manufacture the antigen themselves, which triggers an immune response.